

Supplementary Table 1

Univariate analyses of 5-year overall survival (OS) according to clinicopathological features in the validation set (n=1041).

Variable	Stage II and low-risk stage III				High-risk stage III			
	Total number	n (%)	HR (95% CI)	P-value	Total number	n (%)	HR (95% CI)	P-value
Age	598	598 (100%)	1.03 (1.00-1.06)	0.034	394	394 (100%)	1.01 (0.99-1.02)	0.52
Gender	598			0.19	394			0.72
Male		342 (57%)	Ref.			234 (59%)	Ref.	
Female		256 (43%)	0.71 (0.43-1.19)			160 (41%)	1.07 (0.76-1.50)	
Randomised adjuvant treatment	598			0.36	394			0.12
CAP		295 (49%)	Ref.			197 (50%)	Ref.	
CAP+BEV		303 (51%)	1.26 (0.77-2.05)			197 (50%)	1.31 (0.93-1.84)	
Sidedness	578			0.90	387			0.001
Right		321 (56%)	Ref.			226 (58%)	Ref.	
Left		257 (44%)	0.97 (0.58-1.60)			161 (42%)	1.75 (1.24-2.47)	
Number of lymph nodes removed	583			0.013	393			0.60
≥12		453 (78%)	Ref.			307 (78%)	Ref.	
<12		130 (22%)	1.92 (1.14-3.23)			86 (22%)	0.89 (0.59-1.35)	
Histological grade	572			0.48	383			0.17
Well		25 (4%)	Ref.			13 (3%)	Ref.	
Moderate		461 (81%)	2.55 (0.35-18.49)			302 (79%)	1.09 (0.40-2.97)	
Poor		86 (15%)	3.18 (0.41-24.62)			68 (18%)	1.62 (0.57-4.63)	
KRAS	555			0.56	358			0.41
Wild type		374 (67%)	Ref.			240 (67%)	Ref.	
Mutated		181 (33%)	1.17 (0.69-1.97)			118 (33%)	1.17 (0.81-1.69)	
BRAF	544			0.031	371			0.093
Wild type		478 (88%)	Ref.			315 (85%)	Ref.	

Mutated		66 (12%)	1.98 (1.05-3.74)			56 (15%)	1.47 (0.93-2.32)	
Microsatellite instability	569			0.50	381			0.74
MSI-H		77 (14%)	Ref.			42 (11%)	Ref.	
MSS		492 (86%)	0.79 (0.40-1.56)			339 (89%)	1.11 (0.61-2.01)	
CD8 ⁺ T-lymphocyte and stroma fraction	598			0.43	394			<0.001
High CD8 fraction and low stroma fraction		282 (47%)	Ref.			138 (35%)	Ref.	
Low CD8 fraction or high stroma fraction		278 (46%)	1.39 (0.83-2.32)			222 (56%)	1.58 (1.05-2.36)	
Low CD8 fraction and high stroma fraction		38 (6%)	1.41 (0.54-3.70)			34 (9%)	2.89 (1.68-4.99)	
CD8 ⁺ T-lymphocyte fraction	598			0.70	394			0.018
High (>2.7%)		331 (55%)	Ref.			174 (44%)	Ref.	
Low (<=2.7%)		267 (45%)	1.10 (0.68-1.79)			220 (56%)	1.53 (1.07-2.18)	
Stroma fraction	598			0.12	394			0.004
Low (<56%)		511 (85%)	Ref.			324 (82%)	Ref.	
High (>=56%)		87 (15%)	1.59 (0.88-2.88)			70 (18%)	1.75 (1.19-2.58)	

Definition: low-risk stage III, pathological tumour stage (pT) 3 pathological lymph node stage (pN) 1 with neither lymphatic nor vascular invasion; high-risk stage III, stage III pT3 N1 with lymphatic and/or vascular invasion, pT4, or pN2. Abbreviation: HR, hazard risk; CI, confidence interval; Ref, reference; CAP, capecitabine; BEV, bevacizumab; MSI-H, microsatellite instability-high; MSS, microsatellite stable.